With the 3-weekly schedule just mentioned, 32% of patients in the ER-/PgR- group and 20.5% in the ER+ and/or PgR+ group achieved a pCR [27]; in the TECHNO study, the pCR rates were 42.3% and 35.4% for patients in the HR- and HR+ populations, respectively [28]; Buzdar al reported a 70.4% of pCR rate in women with ER-/PgR- BC versus 47.6% in women with ER+ or PgR+ disease, with trastuzumab administered with paclitaxel following FEC [29]. The gene discussed is PGR; the disease is breast cancer.